Cancer is one of the leading causes of death in industrialized countries. Major breakthroughs in drug discovery for oncology have been hampered by the high costs and the high attrition rate. Classical human cancer models used are cancer cell lines (2D) and in vivo animal models, which remain to form the basis of today’s efficacy and toxicology testing services.
Although these oncology models have proven to be useful, their utility towards the clinic has vast room for improvement. Because of this, InnoSer has teamed up with leader research groups from both academia and industry to develop innovative platforms and offer them for effective preclinical drug development
These include a collaborative project to establish a variety of PDX/O models. With its two components, patient derived mouse xenografts (PDX) and patient derived organoids (PDO) that are thoroughly characterized in the same manner, PDX/O platform provides a closer to clinic double model (in vitro and in vivo) of the same parental tumor. Since the tissue origin is the human tumor obtained during surgery or biopsy, this approach also contributes to the advances in personalized medicine.
MD, PhD Marije Slingerland
A member of InnoSer’s Scientific Advisory Board, Dr. Slingerland from Leiden University Medical Center focuses on clinical trials in gastrointestinal cancer and in head and neck cancer, particularly on intratumoral immune parameters.
Expanding biobank and PDX / PDO models
Our current collection of 99 samples with pulmonary, pancreatic, biliary, hepatic, gastric, and esophageal origins form the basis of established models.
A number of xenograft, organoid or combined models are already validated and ready for compound testing. For several others, we are happy to collaborate with you, validating the platform with your compounds and providing you results under favourable conditions.
The greatest advantage of this platform is that you will be able to test your compounds coherently both in vitro and in vivo, using the same starting material.
MiniBrain for life-like in vitro conditions
Thanks to our partnership with Neurix, we offer MiniBrain platform for glioblastoma drug development applications. Patient derived samples are inoculated on MiniBrain to regenerate actual tumor conditions.
Since MiniBrain cell composition and characteristics mimic those of human cortical tissue’s, this allows us to watch closely and record all aspects relevant to the tumor growth, including tumor-neural tissue interactions and tumor invasion capacity.
InnoSer’s scientific experts help you design studies for your optimal results and carry out your compound testing in state-of-the-art facilities.
Please feel free to get in touch with our experts by using our project description form.
Powered by imaging capabilities
Particularly in vivo imaging has become a valuable tool for collecting mid study data in animal studies. These non-invasive methods can be applied with high sensitivity and in real time. With InnoSer’s imaging capabilities, track tumorigenicity, tumor progression, and metastasis. Read more >>
Smart pathological assessment
Thanks to our partnership with C-Path, we offer pathological assessment of your samples not only by the experts in the field, but also by having this coupled to smart technologies. AI driven automation and secure cloud storage of your data bring you the best of digital pathology. Read more >>
Scientific experts to guide you
An expert team lead by our immuno-oncology study director Kim Frederix helps you choose the right tools and set up optimal study designs. Curating the preclinical testing of your lead compounds with a deep understanding in the field is your solution to accelarating your drug development.
From early to late preclinical development
Our methods are particularly valuable for medium (10-20 candidates) to low (2-5 candidates) throughput compound testing, with thorough examinations and eventual efficacy, dosing and toxicology analyses.
- Syngeneic subcutaneous or orthotopic tumor growth models
- Analyses of immune populations in tumors, blood markers
- PBMC models for T-cell exhaustion in patient populations
- PK/PD for new compounds in naive / tumor bearing mice
- Determining Maximum Tolerated Doses (MTD) in mice